Shares of Athersys, which have nearly doubled in the past 3 months, should keep their momentum as a number of data points concerning the company's regenerative medicine treatments roll in, says Gil Van Bokkelen, CEO of Athersys. Van Bokkelen says the company's lead drug MultiStem is entering into a number of late stage clinical trials across a number of illnesses. He also says the company is making huge strides with patents in Japan and has successfully raised enough cash to carry it forward.

Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.

If you liked this article you might like

Athersys (ATHX) Strong On High Relative Volume Today

Should You Buy Into Athersys’ Latest Spin on Failed Stroke Therapy?

Here’s Why Athersys (ATHX) Stock is Jumping Today

Athersys (ATHX) Stock Advances on Healios Licensing Agreement

5 Breakout Stocks Under $10 Set to Soar